<?xml version="1.0" encoding="UTF-8"?>
<document>
<type>mainstream</type>
<forum>http://tickerreport.com/feed/</forum>
<forum_title>Ticker Report</forum_title>
<discussion_title>RBC Capital Markets Reaffirms Buy Rating for Vertex Pharmaceuticals Inc. (VRTX)</discussion_title>
<language>english</language>
<gmt_offset></gmt_offset>
<topic_url>http://www.tickerreport.com/banking-finance/2084363/rbc-capital-markets-reaffirms-buy-rating-for-vertex-pharmaceuticals-inc-vrtx-2/</topic_url>
<topic_text>
Tweet 
RBC Capital Markets restated their buy rating on shares of Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) in a report published on Tuesday morning. 
In related news, Director Joshua S. Boger sold 5,130 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, June 1st. The stock was sold at an average price of $93.65, for a total transaction of $480,424.50. Following the sale, the director now directly owns 268,225 shares in the company, valued at $25,119,271.25. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink . Also, Director Joshua S. Boger sold 47,000 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, August 3rd. The stock was sold at an average price of $100.66, for a total value of $4,731,020.00. Following the sale, the director now owns 274,725 shares in the company, valued at $27,653,818.50. The disclosure for this sale can be found here . 
A number of hedge funds have modified their holdings of VRTX. BlueMountain Capital Management LLC raised its stake in shares of Vertex Pharmaceuticals by 69.3% in the first quarter. BlueMountain Capital Management LLC now owns 1,867 shares of the pharmaceutical company’s stock worth $148,000 after buying an additional 764 shares during the period. Checchi Capital Advisers LLC increased its stake in Vertex Pharmaceuticals by 4.3% in the second quarter. Checchi Capital Advisers LLC now owns 1,763 shares of the pharmaceutical company’s stock worth $152,000 after buying an additional 73 shares in the last quarter. Howard Hughes Medical Institute increased its stake in Vertex Pharmaceuticals by 13.0% in the first quarter. Howard Hughes Medical Institute now owns 2,000 shares of the pharmaceutical company’s stock worth $159,000 after buying an additional 230 shares in the last quarter. ING Groep NV purchased a new stake in Vertex Pharmaceuticals during the second quarter worth about $204,000. Finally, Douglass Winthrop Advisors LLC purchased a new stake in Vertex Pharmaceuticals during the second quarter worth about $215,000. 
Several other equities research analysts have also recently weighed in on VRTX. Robert W. Baird reissued a buy rating on shares of Vertex Pharmaceuticals in a research note on Monday, April 25th. Zacks Investment Research cut Vertex Pharmaceuticals from a hold rating to a strong sell rating in a research note on Tuesday, April 26th. Royal Bank Of Canada decreased their price target on Vertex Pharmaceuticals from $135.00 to $115.00 and set an outperform rating for the company in a research note on Thursday, April 28th. Goldman Sachs Group Inc. cut Vertex Pharmaceuticals from a buy rating to a neutral rating and decreased their price target for the company from $109.00 to $88.00 in a research note on Thursday, April 28th. Finally, Barclays PLC decreased their target price on Vertex Pharmaceuticals from $135.00 to $110.00 and set an overweight rating for the company in a research note on Thursday, April 28th. Nine investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $120.43. 
Vertex Pharmaceuticals ( NASDAQ:VRTX ) opened at 98.01 on Tuesday. Vertex Pharmaceuticals has a 52-week low of $75.90 and a 52-week high of $136.97. The firm’s 50 day moving average price is $95.19 and its 200 day moving average price is $88.19. The firm’s market cap is $24.28 billion. 
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Wednesday, July 27th. The pharmaceutical company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.03. The company earned $431.61 million during the quarter, compared to analyst estimates of $428.08 million. During the same period in the previous year, the company posted ($0.54) EPS. The company’s quarterly revenue was up 159.9% on a year-over-year basis. Equities research analysts anticipate that Vertex Pharmaceuticals will post $1.04 EPS for the current fiscal year. 
Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.   Vertex Pharmaceuticals Inc.   Vertex Pharmaceuticals Inc.  
</topic_text>
<spam_score>0.00</spam_score>
<post_num>1</post_num>
<post_id>post-1</post_id>
<post_url>http://www.tickerreport.com/banking-finance/2084363/rbc-capital-markets-reaffirms-buy-rating-for-vertex-pharmaceuticals-inc-vrtx-2/</post_url>
<post_date>20160822</post_date>
<post_time>0748</post_time>
<username>Stephan Byrd</username>
<post>
Tweet 
RBC Capital Markets restated their buy rating on shares of Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) in a report published on Tuesday morning. 
In related news, Director Joshua S. Boger sold 5,130 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, June 1st. The stock was sold at an average price of $93.65, for a total transaction of $480,424.50. Following the sale, the director now directly owns 268,225 shares in the company, valued at $25,119,271.25. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink . Also, Director Joshua S. Boger sold 47,000 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, August 3rd. The stock was sold at an average price of $100.66, for a total value of $4,731,020.00. Following the sale, the director now owns 274,725 shares in the company, valued at $27,653,818.50. The disclosure for this sale can be found here . 
A number of hedge funds have modified their holdings of VRTX. BlueMountain Capital Management LLC raised its stake in shares of Vertex Pharmaceuticals by 69.3% in the first quarter. BlueMountain Capital Management LLC now owns 1,867 shares of the pharmaceutical company’s stock worth $148,000 after buying an additional 764 shares during the period. Checchi Capital Advisers LLC increased its stake in Vertex Pharmaceuticals by 4.3% in the second quarter. Checchi Capital Advisers LLC now owns 1,763 shares of the pharmaceutical company’s stock worth $152,000 after buying an additional 73 shares in the last quarter. Howard Hughes Medical Institute increased its stake in Vertex Pharmaceuticals by 13.0% in the first quarter. Howard Hughes Medical Institute now owns 2,000 shares of the pharmaceutical company’s stock worth $159,000 after buying an additional 230 shares in the last quarter. ING Groep NV purchased a new stake in Vertex Pharmaceuticals during the second quarter worth about $204,000. Finally, Douglass Winthrop Advisors LLC purchased a new stake in Vertex Pharmaceuticals during the second quarter worth about $215,000. 
Several other equities research analysts have also recently weighed in on VRTX. Robert W. Baird reissued a buy rating on shares of Vertex Pharmaceuticals in a research note on Monday, April 25th. Zacks Investment Research cut Vertex Pharmaceuticals from a hold rating to a strong sell rating in a research note on Tuesday, April 26th. Royal Bank Of Canada decreased their price target on Vertex Pharmaceuticals from $135.00 to $115.00 and set an outperform rating for the company in a research note on Thursday, April 28th. Goldman Sachs Group Inc. cut Vertex Pharmaceuticals from a buy rating to a neutral rating and decreased their price target for the company from $109.00 to $88.00 in a research note on Thursday, April 28th. Finally, Barclays PLC decreased their target price on Vertex Pharmaceuticals from $135.00 to $110.00 and set an overweight rating for the company in a research note on Thursday, April 28th. Nine investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $120.43. 
Vertex Pharmaceuticals ( NASDAQ:VRTX ) opened at 98.01 on Tuesday. Vertex Pharmaceuticals has a 52-week low of $75.90 and a 52-week high of $136.97. The firm’s 50 day moving average price is $95.19 and its 200 day moving average price is $88.19. The firm’s market cap is $24.28 billion. 
Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Wednesday, July 27th. The pharmaceutical company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.03. The company earned $431.61 million during the quarter, compared to analyst estimates of $428.08 million. During the same period in the previous year, the company posted ($0.54) EPS. The company’s quarterly revenue was up 159.9% on a year-over-year basis. Equities research analysts anticipate that Vertex Pharmaceuticals will post $1.04 EPS for the current fiscal year. 
Vertex Pharmaceuticals Incorporated is engaged in the business of discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company operates in pharmaceuticals segment. Its business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.   Vertex Pharmaceuticals Inc.   Vertex Pharmaceuticals Inc.  
</post>
<signature>

</signature>
<external_links>

</external_links>
<country>US</country>
<main_image>http://www.tickerreport.com/logos/vertex-pharmaceuticals-logo.png</main_image>
</document>
